AstraZeneca PLC (AZN) said it has reached a $520 million agreement "in principle" to settle a U.S. investigation into the company's marketing of schizophrenia drug Seroquel.
The U.S. Attorney's Office in Philadelphia has been leading an investigation into AstraZeneca's marketing of Seroquel, including allegations that the company promoted the drug for uses for which it is not approved by the Food and Drug Administration, the company said Thursday.
more at Nasdaq.com
Not much, comparing to Pfizer and Eli Lilly!
Subscribe to:
Post Comments (Atom)
Posts
No comments:
Post a Comment